

**Monoclonal Antibodies for COVID-19:
Pharmacist Focus on the Rapidly Evolving Treatment Landscape**

Recorded PODCAST

Key References

1. Cucinotta D, Vanelli M. Who declares covid-19 a pandemic. *Acta Biomed.* 2020;91(1):157-160.
2. WHO Coronavirus (COVID-19) Dashboard. World Health Organization (WHO). <https://covid19.who.int/>. Accessed February 1, 2022.
3. COVID Data Tracker: United States at a Glance. Centers for Disease Control and Prevention (CDC). <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>. Accessed February 1, 2022.
4. Gustine JN, Jones D. Immunopathology of hyperinflammation in covid-19. *Am J Pathol.* 2021;191(1):4-17.
5. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *Lancet.* 2020;395(10224):565-574.
6. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19. *N Engl J Med.* 2020;383(2):120-128.
7. NIH COVID-19 Treatment Guidelines. National Institutes of Health (NIH). <https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/>. Accessed February 1, 2022.
8. Agarwal A, Rochweg B, Lamontagne F, et al. A living WHO guideline on drugs for covid-19. *BMJ.* <https://www.bmj.com/content/370/bmj.m3379>. Accessed February 1, 2022.
9. Jiang S, Hillyer C, Du L. Neutralizing antibodies against sars-cov-2 and other human coronaviruses. *Trends Immunol.* 2020;41(5):355-359.
10. Bamlanivimab and etesevimab [fact sheet for health care providers Emergency Use Authorization (EUA)]. Indianapolis, IN: Eli Lilly and Company. 2021.
11. Regen-COV[®] (casirivimab and imdevimab) [fact sheet for health care providers Emergency Use Authorization (EUA)]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc. 2021.
12. Sotrovimab [fact sheet for health care providers Emergency Use Authorization (EUA)]. Philadelphia, PA: GlaxoSmithKline LLC. 2021.
13. Evusheld[™] (tixagevimab co-packaged with cilgavimab) [fact sheet for health care providers Emergency Use Authorization (EUA)]. Wilmington, DE: AstraZeneca Pharmaceuticals LP. 2021.
14. Anti-SARS-CoV-2 monoclonal antibodies. National Institutes of Health (NIH). <https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/anti-sars-cov-2-monoclonal-antibodies/>. Accessed February 2, 2022.

15. Monoclonal antibody COVID-19 infusion. Centers for Medicare & Medicaid Services (CMS). <https://www.cms.gov/medicare/covid-19/monoclonal-antibody-covid-19-infusion>. Accessed February 2, 2022.
16. Dougan M, Azizad M, Mocherla B, et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. *Clin Infect Dis*. Published online October 28, 2021:ciab912.
17. Dougan M, Nirula A, Azizad M, et al. Bamlanivimab plus etesevimab in mild or moderate covid-19. *N Engl J Med*. 2021;385(15):1382-1392.
18. Weinreich DM, Sivapalasingam S, Norton T, et al. Regen-COV antibody combination and outcomes in outpatients with covid-19. *N Engl J Med*. 2021;385(23):e81.
19. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early treatment for covid-19 with sars-cov-2 neutralizing antibody sotrovimab. *N Engl J Med*. 2021;385(21):1941-1950.
20. Levin MJ, Ustianowski A, De Wit S, et al. Lb5. Provent: phase 3 study of efficacy and safety of azd7442 (Tixagevimab/cilgavimab) for pre-exposure prophylaxis of covid-19 in adults. *Open Forum Infect Dis*. 2021;8(Supplement_1):S810-S810.
21. People with certain medical conditions. Centers for Disease Control and Prevention (CDC). <https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>. Updated December 14, 2021. Accessed February 2, 2022.
22. The COVID-19 treatment guidelines panel's statement on therapies for high-risk, nonhospitalized patients with mild to moderate COVID-19. National Institutes of Health (NIH). <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/>. Accessed February 2, 2022.
23. The COVID-19 treatment guidelines panel's interim statement on patient prioritization for outpatient anti-SARS-CoV-2 therapies or preventive strategies when there are logistical or supply constraints. National Institutes of Health (NIH). <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-patient-prioritization-for-outpatient-therapies/>. Accessed February 2, 2022.
24. COMBATCOVID. Health and Human Services (HHS). <https://combatcovid.hhs.gov/possible-treatment-options-covid-19/monoclonal-antibodies-high-risk-covid-19-positive-patients>. Accessed February 2, 2022.

Combat COVID Monoclonal Antibodies Call Center

Toll-free numbers to help access therapy: 1-877-332-6585 (English) and 1-877-366-0310 (Spanish)